To Study the Use of Humanized CD25 in Preventing the Relapse of Psoriasis Vulgaris

Completed · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Psoriasis

In brief

This study is designed to study disease relapse after NBUVB and how the administration of Daclizumab/placebo alters disease relapse.

Key facts

Study ID: NCT00050661
Run by: Rockefeller University
People needed: 6
Starts: 1997-10-01
Expected to finish: 2008-04-01
Last updated by the study team: 2009-03-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Male or female patients with chronic psoriasis vulgaris (disease stable or worsening for > 6 months). Patients age 16 - 21 will be considered on a case to case basis.
For those patients under the age of 18, parental consent will be obtained.
Extensive skin involvement.
Scale, thickness, and erythema in individual psoriasis lesions of at least moderate intensity.
Psoriasis treated with emollients only for 2 weeks prior to treatment
Patients with active psoriatic arthritis, if accompanied by psoriasis vulgaris involving more than 5% of the body surface.
Patients that are appropriate for treatment with UVB.

You may not qualify if…

Positive serology for HIV, Hepatitis B, or Hepatitis C.
Positive β-HCG titer. For women of childbearing potential, unwillingness or inability to use a contraceptive device during this study if negative for β-HCG.
Guttate psoriasis, pustular psoriasis, or whole body erythroderma.
Active infection or persistent fever of unknown origin.
Major concurrent illness, which could worsen following treatment with anti-TAC.

Where it is running

Rockefeller University Hospital — New York, New York, United States
Rockefeller University — New York, New York, United States
Rockefeller University — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.